04 September 2025
04 September 2025
Novartis has returned to Argo for rights to a number of the biotech鈥檚 clinical stage assets.
While mental health disorders such as depression are among the leading causes of disability globally, there is a lack of suitable drug interventions for treatment-resistant forms of the disease.
The approval was based on outcomes from the randomised MIRASOL Phase III trial.
Morocco is set to implement a major reform to its Drug Pricing Decree in the coming weeks.
The arrangement grants Avadel rights to develop the therapy worldwide, except for mainland China, Macau and Hong Kong.
Despite a trial failure in Parkinson鈥檚 disease, Novartis is having a second bite of the alpha-synuclein cherry with Arrowhead鈥檚 drug.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
